Clinical Trials · NCT00308438

Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease Who Completed Protocol CL0600-008

CompletedPhase 2Teduglutide (Approved)
Phase
Phase 2
Recruitment status
Completed
Sponsor
Shire
Enrollment
67
Start date
Mar 2004
Locations
24 sites, United States, Canada
Primary endpoint
The percentage of subjects who are in remission (CDAI score less than 150) at week 12 of this study.
View Teduglutide compound reference